Advice

following a full submission assessed under the orphan equivalent medicine process

spesolimab (Spevigo®) is not recommended for use within NHSScotland.

Indication under review: for the treatment of flares in adult patients with generalised pustular psoriasis (GPP) as monotherapy.

In a double-blind, phase II study, spesolimab, compared with placebo, significantly increased the proportion of adults with a moderate-to-severe flare of GPP who achieved pustular clearance.

The submitting company did not present a sufficiently robust clinical and economic analysis to gain acceptance by SMC.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.

Medicine details

Medicine name:
spesolimab (Spevigo)
SMC ID:
SMC2729
Indication:

For the treatment of flares in adult patients with generalised pustular psoriasis (GPP) as monotherapy.

Pharmaceutical company
Boehringer Ingelheim Ltd
BNF chapter
Skin
Submission type
Full
Status
Not recommended
Date advice published
10 March 2025